NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market as soon as next year, CEO Stephane Bancel told Nikkei on Wednesday.
The company is co-developing a messenger RNA vaccine that targets cancer cells with U.S.-based Merck. The launch is targeted for 2027 under the company's basic plan but this can be moved forward, according to Bancel.
